Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the higher rates of advanced prostate cancer diagnoses among black men.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
A £42 million United Kingdom-wide trial, the TRANSFORM trial led by Prostate Cancer UK with £16 million funding from the Government, is under way and aimed at helping find best ways of detecting prostate cancer in men, even if they are not displaying any symptoms and could save thousands of lives.
This study will also aim to address some of the inequalities that exist in prostate cancer diagnosis by targeting black men in trial recruitment. This is vital as previous trials have not included enough black men to adequately demonstrate the harms and benefits of screening for this group specifically, despite their significantly higher risk.
Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the findings in the National Prostate Cancer Audit's State of the Nation Report, published in January, particularly regarding the disparities in health outcomes for black men diagnosed with prostate cancer.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not made a specific assessment of the findings in the National Prostate Cancer Audit's State of the Nation Report. However, the Government understands more needs to be done to improve outcomes for all people with prostate cancer, including for black men.
To address disparities and find ways to better detect prostate cancer, we have invested £16 million in the TRANSFORM trial, aimed at helping to find a way of catching prostate cancer in men, even if they are not displaying any symptoms. This research will ensure that one in ten participants are black men.
Following publication of the 10-Year Health Plan, we will publish a new National Cancer Plan, which will include further details on how we will improve outcomes for all tumour types, including prostate cancer. We are now in discussions about what form that plan should take, and what its relationship to the 10-Year Health Plan and the Government’s wider Health Mission should be. We will provide updates on this in due course.
Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many asthma reviews were conducted in England in each of the five most recent years for which figures are available.
Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)
The Quality Outcomes Framework (QOF) ensures all general practitioner practices establish and maintain a register of patients with an asthma diagnosis in accordance with National Institute for Health and Care Excellence guidance. Part of this guidance includes the provision of an annual Asthma review. The QOF annual review indicator was introduced in 2020/21 and contains Asthma review data from the past two years. In 2020/21 there were 1,132,926 and in 2021/22 there were 1,964,234. The 2022/23 data is to be published in September.
Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what was the annual expenditure on asthma reviews in England for each of the five most recent years for which figures are available.
Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)
NHS England does not hold this information.
Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many people waited for allergy testing for more than 12 weeks in each of the past 10 years.
Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)
This information is not collected centrally.
Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government how many preventable deaths occurred in each of the three most recent years for which figures are available, as a result of (1) failure to administer an adrenaline auto-injector, and (2) failure of an adrenaline auto-injector.
Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)
Data on the number of preventable deaths which have occurred as a result of failure to administer an adrenaline auto-injector and failure of an adrenaline auto-injector are not collected by Medicines and Healthcare products Regulatory Agency (MHRA), as the Human Medicines regulations relate to pharmacovigilance of adverse drug reactions and medication errors resulting in adverse drug reactions. Anyone experiencing side effects with medicines is encouraged to report these to MHRA via Yellow Card.
Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the Government's review of hospital food will include mental health hospitals.
Answered by Jo Churchill
Mental health hospitals are included in the National Health Service hospital food review.
Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to publish an update on progress made on the Sugar Reduction Programme.
Answered by Jo Churchill
The publication date for the second progress report for the sugar reduction programme is yet to be agreed.
Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will publish a list of medicines that are (a) not currently available and (b) in short supply in (i) the West Midlands and (ii) England and Wales.
Answered by Jo Churchill
The Department receives regular reports from the pharmaceutical industry about issues which may potentially interrupt the supply of medicines that may affect United Kingdom patients and uses a host of tools to help mitigate and manage any issues. From January this year, it became a mandatory requirement that pharmaceutical companies must report this information to us in a timely manner.
The Department shares regular updates about impending and current medicine supply issues directly with the National Health Service and the devolved administrations and communicates with other networks including patient groups where appropriate. These communications include information about mitigation actions and management plans to ensure affected patients can be managed appropriately. The Department does not share this information publicly.
Asked by: Lord Watson of Wyre Forest (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the number of EU citizens working for the NHS in the West Midlands that have been granted settled status; and what proportion of those EU citizens this represents.
Answered by Chris Skidmore
Information about the number of European Union citizens working for the National Health Service, in the West Midlands or elsewhere, who have been granted settled status is not held centrally.